Skip to content

Contrast Enhanced Ultrasound and Urine Mass Spectometry in Patients with Hepatocellular Adenoma

Contrast Enhanced Ultrasound and Urine Mass Spectometry in Patients with Hepatocellular Adenoma - nvt

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON36784
Enrollment
78
Registered
2011-07-20
Start date
2012-05-15
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver adenoma

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Persons 18 years and older, discharged from follow-up of the Erasmus MC with the diagnosis or probable diagnosis of hepatocellular adenoma. Informed consent must be signed.

Exclusion criteria

Exclusion criteria: Persons under 18 years.

Design outcomes

Primary

MeasureTime frame
What is the sensitivity of CEUS with SonoVue compared to diagnostic modalities conducted in the past (radiology, histology)?

Secondary

MeasureTime frame
What is the behavior of hepatocellular adenoma during and after menopause? Is it possible to classify hepatocellular adenoma, according to the subgroups of the Bordeaux group, based on contrast ultrasonography? Are there specific biomarkers (natural peptides and metabolites) in urine that can demonstrate hepatocellular adenoma? What is the quality of life of patients with hepatocellular adenoma? 1. with certainty of hepatocellular adenoma (> 6 months ago) 2. who are in a diagnostic process for hepatocellular adenoma

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)